GSK Reports Results of Trelegy Ellipta in P-III CAPTAIN Study for Asthma

 GSK Reports Results of Trelegy Ellipta in P-III CAPTAIN Study for Asthma

GSK Reports Results of Trelegy Ellipta in P-III CAPTAIN Study for Asthma

Shots:

  • The P-III CAPTAIN study involves assessing of Trelegy Ellipta (FF/UMEC/VI) (100/31.25/25, 100/62.5/25, 200/31.25/25 and 200/62.5/25 mcg) vs Relvar/Breo Ellipta (FF/VI) (100/25 and 200/25 mcg) in 2,436 patients with uncontrolled asthma prior treated with ICS/LABA across 15 countries
  • The P-III CAPTAIN study results: met its 1EPs; @24wks. 100/62.5/25mcg vs 200/62.5/25mcg, improvement in lung function & trough FEV1 (110ml &r 92ml); 100/62.5/25 and 200/62.5/25 vs 100/25 and 200/25, 13% reduction in exacerbations
  • Trelegy Ellipta (qd) is an inhaler triple therapy of fluticasone furoate/umeclidinium/vilanterol indicated for the maintenance treatment of airflow obstruction in COPD. In 2017, Trelegy Ellipta (100/62.5/25 mcg) has received FDA’s approval for COPD

Click here to read full press release/ article | Ref: GSK | Image: Caixin Global

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post